An animal model of FM was produced using the protocol described in previous studies (31 (link), 34 (link), 35 (link)). Reserpine (Nacalai Tesque, Inc., Kyoto, Japan), adjusted to a concentration of 0.25 mg/mL with 0.5% acetic acid, was injected (0.25 mg/kg, s.c.) into the back skin once a day for 3 successive days (RES group). As a control, a vehicle solution (0.5% acetic acid) was similarly injected (VEH group).
Reserpine
Manufactured by Nacalai Tesque
Sourced in Japan
Reserpine is a laboratory reagent used in the study of various biological and biochemical processes. It is a phytochemical compound derived from the roots of the Rauwolfia serpentina plant. Reserpine is commonly used as a research tool to investigate the mechanisms of action and effects of certain drugs and neurotransmitters.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using reserpine
1
Reserpine-Induced Animal Model of Fibromyalgia
2
Reserpine-Induced Fibromyalgia in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To induce FM in the model mice, Reserpine was injected through the intraperitoneal route (1 mL/kg) into wild-type mice once a day for 3 days (Nagakura et al., 2009 (link)). Reserpine, purchased from Nacalai Tesque (product No.: 30013-81, Kyoto, Japan), was dissolved in 100% glacial acetic acid (1 mg/0.05 mL) (solution A). Subsequently, distilled water (1 mg/0.95 mL) was added to solution A (solution B, 1 mg/1 mL), containing 5% glacial acetic acid to create solution B. Following this, solution B was diluted to a final concentration of 0.5% acetic acid with distilled water (stock solution), which was subcutaneously injected into the mice 3 times, at a dosage of 1 mL/kg.
3
Reserpine-Induced Fibromyalgia Model in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To induce FM in the mice, an intraperitoneal Reserpine injection (1 mL/kg) was administered to wild-type mice once a day for three days [25 (link)]. Reserpine was purchased from Nacalai Tesque (No. 30013–81, Kyoto, Japan) and dissolved in 100% glacial acetic acid (1 mg/0.05 mL) (A solution). Distilled water (1 mg/0.95 mL) was subsequently added to the A solution (B solution, 1 mg/1 mL), in which 5% glacial acetic acid was contained in the B solution. Further, the B solution was diluted to a final concentration of 0.5% acetic acid with distilled water (stock solution), which was subcutaneously injected into the mice once a day at a dosage of 10 mL/kg for three days. Therefore, one injected dose would constitute 0.3 ml of Reserpine (stock solution) for a mouse with a body weight of 30 g.
4
Reserpine-Induced Muscle Hyperalgesia Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The RIM model, which mimics features of FM, including hyperalgesic symptoms, was generated according to a previously reported method.10 (link) Reserpine, a CNS monoamine depleting substance (Nacalai Tesque Inc., Kyoto, Japan) was dissolved in glacial acetic acid and diluted to a final concentration of 0.5% with distilled water. Rats were administered repeated subcutaneous (SC) injections of 1 mg·kg−1 Reserpine 3 times (once daily, for 3 consecutive days). Drugs were evaluated using a muscle pressure test on Day 7 after the final injection of Reserpine. After the pre-drug muscle pressure test, Reserpine-treated rats were allocated to groups based on their muscle pressure threshold, with each group receiving either vehicle or a dose of the drug. The muscle pressure test was conducted again after administration of vehicle or the drug. Vehicle or ASP0819 was orally administered on Day 8, and the muscle pressure threshold was measured 4 h after administration.
5
Reserpine-Induced Fibromyalgia Model in Rats
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A previously optimized regimen of Reserpine, i.e., 1 mg/kg, subcutaneous, once daily for 3 consecutive days [1] (link), was used to induce a fibromyalgia-like condition in rats. Reserpine (Nacalai Tesque, Kyoto, Japan) was weighed, transferred to a 1.5 mL microtube, and dissolved in glacial acetic acid (FUJIFILM Wako Pure Chemical Co., Osaka, Japan) with sonication. This solution was diluted in a test tube with distilled water, resulting in final concentration of 1 mg/mL Reserpine in 0.5% acetic acid. The injection of Reserpine was initiated when the body weight of animal was <300 g. The Reserpine solution was injected subcutaneously on the back of rats in a volume of 1 mL/kg (i.e., 1 mg Reserpine/kg). The injection was administered once daily for 3 consecutive days. Control animals were injected with vehicle (0.5% acetic acid, 1 mL/kg of body weight).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!